Cutaneous B-Cell Lymphoblastic Lymphoma

Am J Dermatopathol. 2019 Aug;41(8):596-601. doi: 10.1097/DAD.0000000000001347.

Abstract

B-cell lymphoblastic lymphoma (B-LBL) is a malignant neoplasm of immature B cells that accounts for only 10% of all cases of lymphoblastic lymphoma. Most commonly, B-LBL presents as bony lesions, but in rare cases, the disease manifests cutaneously. We present a case of simultaneous cutaneous and systemic presentation of B-LBL in an otherwise healthy 28-year-old man in which the lymphoblastic infiltrate stained positive for CD79a, Tdt, CD10, and CD20. A diagnosis of cutaneous B-LBL was made, and systemic work-up revealed widespread involvement of the skin, bone, and lymph nodes. Review of all currently described cases of cutaneous B-LBL with or without systemic involvement revealed that the most frequently positive tumor markers were CD79a (92.3%), Tdt (90.6%), and CD10 (83.3%). Systemic involvement of B-LBL was found in nearly half of all cases with cutaneous presentation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antigens, CD20 / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis
  • Biopsy
  • CD79 Antigens / analysis
  • DNA Nucleotidylexotransferase / antagonists & inhibitors
  • Dose Fractionation, Radiation
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunohistochemistry
  • Leukemia, Lymphoid / diagnosis*
  • Leukemia, Lymphoid / immunology
  • Leukemia, Lymphoid / pathology
  • Leukemia, Lymphoid / therapy
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / immunology
  • Lymphoma, B-Cell / pathology
  • Lymphoma, B-Cell / therapy
  • Male
  • Neprilysin / analysis
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy
  • Treatment Outcome

Substances

  • Antigens, CD20
  • Biomarkers, Tumor
  • CD79 Antigens
  • CD79A protein, human
  • DNA Nucleotidylexotransferase
  • Neprilysin